PE20091199A1 - Derivado de piperazina que tiene afinidad por el receptor de histamina h3 - Google Patents
Derivado de piperazina que tiene afinidad por el receptor de histamina h3Info
- Publication number
- PE20091199A1 PE20091199A1 PE2008001550A PE2008001550A PE20091199A1 PE 20091199 A1 PE20091199 A1 PE 20091199A1 PE 2008001550 A PE2008001550 A PE 2008001550A PE 2008001550 A PE2008001550 A PE 2008001550A PE 20091199 A1 PE20091199 A1 PE 20091199A1
- Authority
- PE
- Peru
- Prior art keywords
- histamine
- receptor
- affinity
- piperazine derivative
- theta
- Prior art date
Links
- 102000004384 Histamine H3 receptors Human genes 0.000 title abstract 2
- 108090000981 Histamine H3 receptors Proteins 0.000 title abstract 2
- GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical class C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 title abstract 2
- -1 HYDROCHLORIDE COMPOUND Chemical class 0.000 abstract 2
- 150000003839 salts Chemical class 0.000 abstract 2
- 208000024827 Alzheimer disease Diseases 0.000 abstract 1
- UGFAIRIUMAVXCW-UHFFFAOYSA-N Carbon monoxide Chemical compound [O+]#[C-] UGFAIRIUMAVXCW-UHFFFAOYSA-N 0.000 abstract 1
- 208000018737 Parkinson disease Diseases 0.000 abstract 1
- CIUQDSCDWFSTQR-UHFFFAOYSA-N [C]1=CC=CC=C1 Chemical compound [C]1=CC=CC=C1 CIUQDSCDWFSTQR-UHFFFAOYSA-N 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 201000000980 schizophrenia Diseases 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
- C07D309/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
- C07D309/08—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D309/10—Oxygen atoms
- C07D309/12—Oxygen atoms only hydrogen atoms and one oxygen atom directly attached to ring carbon atoms, e.g. tetrahydropyranyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Psychology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Anesthesiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Pyrane Compounds (AREA)
Abstract
SE REFIERE A UN COMPUESTO HIDROCLORURO DE 1-(1-METILETIL)-4-{[4-(TETRAHIDRO-2H-PIRAN-4-ILOXI)FENIL]CARBONIL}PIPERAZINA DE FORMULA (I) Y SUS SALES CRITALINAS DE FORMAS 1 Y 2. LA SAL CRISTALINA DE FORMA 1 TIENE UN PATRON DE DIFRACCION DE RAYOS X DE POLVO EXPRESADOS EN GRADOS 2 THETA DE 6,4±0,1; 12,7±0,1; 15,4±0,1; 15,7±0,1; 17,1±0,1; 19,1±0,1; 19,7±0,1; 21,9±0,1; 25,5±0,1; 27,0±0,1 Y 28,2±0,1. LA SAL CRISTALINA DE FORMA 2 TIENE UN PATRON DE DIFRACCION DE RAYOS X DE POLVO EXPRESADOS EN GRADOS 2 THETA DE 6,4±0,1; 12,8±0,1; 15,4±0,1; 19,2±0,1; 19,7±0,1; 20,0±0,1; 21,8±0,1; 21,9±0,1; 23,5±0,1; 24,65±0,1 (o 24,7±0,1); 25,8±0,1 y 27,0±0,1. SE REFIERE TAMBIEN A UNA COMPOSICION FARMACEUTICA QUE COMPRENDE LA FORMA CRISTALINA Y A UN PROCEDIMIENTO DE SU PREPARACION. DICHOS COMPUESTOS SON MODULADORES DEL RECEPTOR DE HISTAMINA H3, POR LO QUE SON UTILES PARA EL TRAMIENTO ENFERMEDAD DE ALZHEIMER, ENFERMEDAD DE PARKINSON, ESQUIZOFRENIA, ENTRE OTRAS
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB0717336A GB0717336D0 (en) | 2007-09-06 | 2007-09-06 | Novel compound |
| GB0814987A GB0814987D0 (en) | 2008-08-15 | 2008-08-15 | Novel compound |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20091199A1 true PE20091199A1 (es) | 2009-09-12 |
Family
ID=39885024
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2008001550A PE20091199A1 (es) | 2007-09-06 | 2008-09-04 | Derivado de piperazina que tiene afinidad por el receptor de histamina h3 |
Country Status (17)
| Country | Link |
|---|---|
| US (2) | US8288389B2 (es) |
| EP (1) | EP2195307B1 (es) |
| JP (1) | JP5379796B2 (es) |
| KR (1) | KR20100059944A (es) |
| CN (1) | CN101848903A (es) |
| AR (1) | AR068370A1 (es) |
| AT (1) | ATE554081T1 (es) |
| AU (1) | AU2008294708B2 (es) |
| BR (1) | BRPI0816304A2 (es) |
| CA (1) | CA2697941A1 (es) |
| CL (1) | CL2008002622A1 (es) |
| EA (1) | EA201070338A1 (es) |
| ES (1) | ES2384414T3 (es) |
| MX (1) | MX2010002606A (es) |
| PE (1) | PE20091199A1 (es) |
| TW (1) | TW200918527A (es) |
| WO (1) | WO2009030716A1 (es) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0324159D0 (en) | 2003-10-15 | 2003-11-19 | Glaxo Group Ltd | Novel compounds |
| US9108948B2 (en) | 2006-06-23 | 2015-08-18 | Abbvie Inc. | Cyclopropyl amine derivatives |
| NZ597498A (en) | 2006-06-23 | 2013-06-28 | Abbvie Bahamas Ltd | Cyclopropyl amine derivatives as histamin H3 receptor modulators |
| CN101848903A (zh) * | 2007-09-06 | 2010-09-29 | 葛兰素集团有限公司 | 对组胺h3受体具有亲和性的哌嗪衍生物 |
| US20110190274A1 (en) * | 2008-08-15 | 2011-08-04 | Glaxo Group Limited | Salt of, and processes for the preparation of, 1-isopropyl-4-hexahydro-1h-1,4-diazepine |
| US9186353B2 (en) | 2009-04-27 | 2015-11-17 | Abbvie Inc. | Treatment of osteoarthritis pain |
| WO2012037258A1 (en) | 2010-09-16 | 2012-03-22 | Abbott Laboratories | Processes for preparing 1,2-substituted cyclopropyl derivatives |
| NZ614567A (en) | 2011-02-23 | 2014-07-25 | Suven Life Sciences Ltd | Novel compounds as histamine h3 receptor ligands |
| WO2013151982A1 (en) | 2012-04-03 | 2013-10-10 | Arena Pharmaceuticals, Inc. | Methods and compounds useful in treating pruritus, and methods for identifying such compounds |
| EP2647377A1 (en) | 2012-04-06 | 2013-10-09 | Sanofi | Use of an h3 receptor antagonist for the treatment of alzheimer's disease |
| PL2888243T3 (pl) | 2012-08-23 | 2017-01-31 | Suven Life Sciences Limited | Związki akryloamidowe jako ligandy receptora histaminowego H3 |
| US10183938B2 (en) | 2014-12-16 | 2019-01-22 | Axovant Sciences Gmbh | Geminal substituted quinuclidine amide compounds as agonists of α-7 nicotonic acetylcholine receptors |
| EP3307269A4 (en) | 2015-06-10 | 2019-02-20 | Axovant Sciences GmbH | AMINOBENZIS OXAZOL COMPOUNDS AS AGONISTS OF A7 NICOTINE ACETYLCHOLIN RECEPTORS |
| WO2017027600A1 (en) | 2015-08-12 | 2017-02-16 | Forum Pharmaceuticals, Inc. | GEMINAL SUBSTITUTED AMINOBENZISOXAZOLE COMPOUNDS AS AGONISTS OF α7-NICOTINIC ACETYLCHOLINE RECEPTORS |
| EP3378477A1 (en) * | 2017-03-21 | 2018-09-26 | BIOPROJET Pharma | New therapeutical use of h3-ligands |
Family Cites Families (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP3476203B2 (ja) | 1997-02-24 | 2003-12-10 | ザイモジュネティックス インコーポレイテッド | カルシトニン擬似体 |
| US6268367B1 (en) | 1998-02-23 | 2001-07-31 | Zymogenetics, Inc. | Piperazine derivatives for treating bone deficit conditions |
| MXPA03000458A (es) | 2000-07-20 | 2004-06-02 | Neurogen Corp | Ligandos receptores de capsaicina. |
| ATE354568T1 (de) | 2000-08-08 | 2007-03-15 | Ortho Mcneil Pharm Inc | Nicht-imidazol aryloxypiperidine als h3 rezeptor liganden |
| EP1421071B1 (en) | 2001-07-02 | 2009-11-18 | High Point Pharmaceuticals, LLC | Substituted piperazine and diazepane derivaives as histamine h3 receptor modulators |
| DE10144226A1 (de) | 2001-09-07 | 2003-03-27 | Henkel Kgaa | Neue verbrückte p-Phenylendiamine |
| EA007983B1 (ru) | 2001-09-19 | 2007-02-27 | Авентис Фарма С.А. | Индолизины в качестве ингибиторов киназных белков |
| WO2003066604A2 (en) | 2002-02-05 | 2003-08-14 | Novo Nordisk A/S | Novel aryl- and heteroarylpiperazines |
| GB0224084D0 (en) | 2002-10-16 | 2002-11-27 | Glaxo Group Ltd | Novel compounds |
| JP2006512404A (ja) | 2002-10-22 | 2006-04-13 | グラクソ グループ リミテッド | Ｈ３受容体リガンドとしてのアリールオキシアルキルアミン誘導体 |
| SI1558595T1 (sl) | 2002-10-23 | 2010-03-31 | Janssen Pharmaceutica Nv | Piperazinilni in diazapanilni benzamidi in benztioamidi |
| PL220722B1 (pl) | 2002-12-20 | 2015-12-31 | Glaxo Group Ltd | Benzoazepinowe pochodne, zawierająca je kompozycja farmaceutyczna i ich zastosowania do wytwarzania leku i do leczenia chorób neurologicznych |
| US7449464B2 (en) | 2003-03-12 | 2008-11-11 | Kudos Pharmaceuticals Limited | Phthalazinone derivatives |
| DK1615909T3 (da) | 2003-04-23 | 2008-11-17 | Glaxo Group Ltd | Piperazin-derivater og deres anvendelse til behandling af neurologiske og psykiatriske sygdomme |
| GB0324159D0 (en) | 2003-10-15 | 2003-11-19 | Glaxo Group Ltd | Novel compounds |
| US20080045506A1 (en) | 2004-10-15 | 2008-02-21 | Glaxo Group Limited | Pyrrolidine Derivatives as Histamine Receptors Ligands |
| EP2404911A1 (en) | 2005-10-31 | 2012-01-11 | Janssen Pharmaceutica NV | Novel processes for the preparation of piperazinyl and diazapanyl benzamide derivatives |
| BRPI0618076A2 (pt) | 2005-10-31 | 2011-08-16 | Janssen Pharmaceutica Nv | processos para a preparação de derivados de ciclopropil-amida |
| SG177207A1 (en) | 2006-12-14 | 2012-01-30 | Janssen Pharmaceutica Nv | Process for the preparation of piperazinyl and diazepanyl benzamide derivatives |
| NZ584100A (en) | 2007-08-22 | 2011-07-29 | Astrazeneca Ab | Cyclopropyl amide derivatives |
| CN101848903A (zh) | 2007-09-06 | 2010-09-29 | 葛兰素集团有限公司 | 对组胺h3受体具有亲和性的哌嗪衍生物 |
| CN101868454A (zh) | 2007-11-20 | 2010-10-20 | 詹森药业有限公司 | 作为组胺h3受体调节剂的环烷基氧基吡啶化合物和杂环烷基氧基吡啶化合物 |
| US9186353B2 (en) * | 2009-04-27 | 2015-11-17 | Abbvie Inc. | Treatment of osteoarthritis pain |
-
2008
- 2008-09-04 CN CN200880115043A patent/CN101848903A/zh active Pending
- 2008-09-04 EP EP08803634A patent/EP2195307B1/en active Active
- 2008-09-04 JP JP2010523502A patent/JP5379796B2/ja not_active Expired - Fee Related
- 2008-09-04 WO PCT/EP2008/061664 patent/WO2009030716A1/en active Application Filing
- 2008-09-04 PE PE2008001550A patent/PE20091199A1/es not_active Application Discontinuation
- 2008-09-04 US US12/676,158 patent/US8288389B2/en not_active Expired - Fee Related
- 2008-09-04 AR ARP080103850A patent/AR068370A1/es unknown
- 2008-09-04 CA CA2697941A patent/CA2697941A1/en not_active Abandoned
- 2008-09-04 EA EA201070338A patent/EA201070338A1/ru unknown
- 2008-09-04 ES ES08803634T patent/ES2384414T3/es active Active
- 2008-09-04 TW TW097133837A patent/TW200918527A/zh unknown
- 2008-09-04 US US12/203,946 patent/US20090170869A1/en not_active Abandoned
- 2008-09-04 BR BRPI0816304 patent/BRPI0816304A2/pt not_active IP Right Cessation
- 2008-09-04 KR KR1020107007395A patent/KR20100059944A/ko not_active Application Discontinuation
- 2008-09-04 AU AU2008294708A patent/AU2008294708B2/en not_active Expired - Fee Related
- 2008-09-04 AT AT08803634T patent/ATE554081T1/de active
- 2008-09-04 CL CL2008002622A patent/CL2008002622A1/es unknown
- 2008-09-04 MX MX2010002606A patent/MX2010002606A/es not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| ATE554081T1 (de) | 2012-05-15 |
| CL2008002622A1 (es) | 2009-11-27 |
| WO2009030716A1 (en) | 2009-03-12 |
| ES2384414T3 (es) | 2012-07-04 |
| JP5379796B2 (ja) | 2013-12-25 |
| CN101848903A (zh) | 2010-09-29 |
| CA2697941A1 (en) | 2009-03-12 |
| TW200918527A (en) | 2009-05-01 |
| KR20100059944A (ko) | 2010-06-04 |
| AU2008294708A1 (en) | 2009-03-12 |
| EP2195307A1 (en) | 2010-06-16 |
| AR068370A1 (es) | 2009-11-11 |
| JP2010538041A (ja) | 2010-12-09 |
| AU2008294708B2 (en) | 2012-03-15 |
| US20100204242A1 (en) | 2010-08-12 |
| MX2010002606A (es) | 2010-03-30 |
| EA201070338A1 (ru) | 2010-10-29 |
| BRPI0816304A2 (pt) | 2015-03-17 |
| US8288389B2 (en) | 2012-10-16 |
| EP2195307B1 (en) | 2012-04-18 |
| US20090170869A1 (en) | 2009-07-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20091199A1 (es) | Derivado de piperazina que tiene afinidad por el receptor de histamina h3 | |
| AR114946A2 (es) | Formas cristalinas de 3-(2,6-dicloro-3,5-dimetoxi-fenil)-1-{6-[4-(4-etil-piperazin-1-il)-fenil-amino]-pirimidin-4-il}-1-metil-urea y sales de las mismas | |
| CO6331340A2 (es) | Pirrolo-pirimidinas y pirrolo piridinas | |
| BRPI0600795A (pt) | forma betad-cristalina de cloridrato de ivabradina, um processo para preparação do mesmo e composições farmacêuticas contendo o mesmo | |
| BRPI0600623A (pt) | forma beta-cristalina de cloridrato de ivabradina, processo para preparação do mesmo e composições farmacêuticas contendo o mesmo | |
| PE20141824A1 (es) | Compuestos terapeuticamente activos y sus metodos de uso | |
| ECSP056127A (es) | Inhibidores de 3-quinasa de fosfatidil-inositol | |
| UY29856A1 (es) | Forma cristalina 8d del clorhidrato de la ivabradina, su procedimiento de preparación, y las composiciones farmaceuticas que la contienen | |
| CU20120013A7 (es) | Derivados de oxacina y su uso como inhibidores de bace para el tratamiento de trastornos neurológicos | |
| UY29766A1 (es) | Formas cristalinas delta y épsilon de mesilato de imatinib | |
| IL189191A0 (en) | Thiazolyl piperidine derivatives useful as h3 receptor modulators | |
| UY30136A1 (es) | Sal especifica, forma anhidra y cristalina de un derivado de dihidropteridiona | |
| BRPI0600796B8 (pt) | forma gama-cristalina de cloridrato de ivabradina, processo para preparação do mesmo e composições farmacêuticas contendo o mesmo | |
| DOP2010000028A (es) | Preparacion solida que contiene alogliptina y clorhidrato de metformina | |
| BRPI0604250A (pt) | forma cristalina delta de cloridrato de ivabradina, processo para sua preparação e composições farmacêuticas contendo a mesma | |
| BRPI0809890A2 (pt) | Processo para preparar imatinib ou sal do mesmo e composição farmacêutica | |
| CY1112233T1 (el) | Παραγωγα 1,2,3-τριαζολης για χρηση ως αναστολεις στεατοϋλο-coa δεσατουρασης | |
| MX2011013437A (es) | Antagonista y agonistas inversos de histamina h3 y metodos para el uso de los mismos. | |
| PE20141148A1 (es) | Mesilato de n-[5-(aminosulfonil)-4 metil-1-3-tiazol-2-il]-n-metil-2-[4-(2-piridinil)fenil]acetamida monohidrato | |
| MY169274A (en) | Fused, tricyclic sulfonamide inhibitors of gamma secretase | |
| PL1888514T3 (pl) | Sole podstawionych estrów kwasu alofanowego i ich zastosowanie w środkach leczniczych | |
| CO6361988A2 (es) | Forma cristalina de un compuesto de 4-[2-(2-fluorofenoximetil)fenil]piperidina. | |
| ES2531159T3 (es) | Compuestos y métodos para el tratamiento del cáncer | |
| BRPI0708278B8 (pt) | forma cristalina "a" do sal de arginina de perindopril, seu uso, processo para sua preparação e composição farmacêutica | |
| ATE524171T1 (de) | Verwendung von 2-(2-nitro-4- trifluormethylbenzoyl)-1,3-cyclohexandion bei der behandlung der parkinson-krankheit |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FD | Application declared void or lapsed |